GAO to report on non-inferiority trials
Executive Summary
Four Congressional Democrats and Sen. Charles Grassley (R-Iowa) have requested a Government Accountability Office report on FDA's use of non-inferiority trials. The request specifically mentions Sanofi-Aventis' antibiotic Ketek, which recently updated its label following reports of hepatoxicity and has been the subject of scrutiny from Grassley (1"The Pink Sheet" July 3, 2006, p. 7). GAO is tasked with reporting on approvals over the past decade from the Office of Antimicrobial Products based on non-inferiority trials. The request also seeks information on FDA's precautions against "bio-creep," the approval of products based on successively less effective comparator agents...
You may also be interested in...
Ketek Labeling Gets Updated Warning, But Not Format, After Liver Toxicity
Sanofi-Aventis is making a relatively modest labeling change to its antibiotic Ketek (telithromycin) following reports of hepatoxicity
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.